Longwood Construction Notice: Ongoing construction near our Longwood campus may affect traffic in the area. Check the latest access changes before you travel. If you are a journalist and have a ...
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
Today, Dana-Farber Cancer Institute announced its intent to file an application for Determination of Need (DON) with the Massachusetts Department of Public Health (DPH) to develop additional ...
Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow ...
Dr. Rotow received her M.D. from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training ...
Dana-Farber/New Hampshire Oncology-Hematology provides expert cancer care in Londonderry, NH. The center makes it possible to offer the expertise and experience of Dana-Farber, New England's leading ...
Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or ...
RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic ...
A large population-based study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Mass General Brigham suggests that genetic testing added to routine newborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results